EVATTUM · Ex vivo assessment of therapy for brain tumors
FP6 — Marie Curie Actions (Human Resources and Mobility)
- Duration
- 2004-03-01 → 2008-02-29
- EU contribution
- €130,035
- Participants
- 2
- Scheme
- TOK
Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.
Results in brief
Final Activity Report Summary - EVATTUM (Ex vivo assessment of therapy for brain tumors)
The main objective of this project was to transfer the ISIS platform developed by INSERM, France, to Capsant Neurotechnologies, United Kingdom. The ISIS platform is a model of the most malignant grade of brain tumour with a median survival time of less than 12 months. Current methods of treatment, such as surgery, radiotherapy and chemotherapy have shown little efect on GBM patient prognosis. GBM tumours are highly invasive, proliferative and angiogenic and therefore there is a poor survival rate for GBM patients. The results of this technology transfer project were as follows: 1) The INSERM ISIS platform was transferred to Capsant Neurotechnologies. This involved training of Capsant staff by INSERM staff. The appropriate equipment was bought in and set-up at Capsant. Different cell lines were tested in the system along with different tissue sources for preparing the slice platform. 2) Using specialised software, the platform was validated for low throughput quantification of morphological differences between different types of tumours and treatments. 3) The system was validated for low-throughput screening for anti-tumour drugs. 4) The platform was analysed and improved for developing the ISIS platform for industrial use. 5) High throughput quantification systems were assessed for industrial use.
Data: CORDIS, © European Union
Project objective
CAPSANT Neurotechnologies is an emerging SME that spun out from the University of Southampton (UK). The scientific and technological basis of the company, that makes its originality and strength on the market, is its unique ability to screen drugs in a fully relevant ex vivo set up.In this set up, experimental models of-up to now- stroke or epilepsy can be analysed in brain slices maintained in organotypic cultures, and outcome measures of neuronal alteration and death provide quantified clues about the protective effects of pharmacological compounds.This platform is currently used for high throughput screening by several industrial partners of CAPSANT Neurotechnologies. Independently, the academic team led by Dr Marc Peschanski at INSERM in Creteil, France, has developed in recent years an experimental model based upon an adaptation of the same methodology, that allows analysing potential therapeutics for an additional brain disease, namely glioblastoma.In addition to allowing proliferation and intra-parenchymal migration of tumour cells to be quantified, this technique (called ISIS for intra-slice implantation system) has revealed instrumental to study tumour-induced angiogenesis. Several molecules endowed with anti-tumoral or anti-angiogenic potentials have already been successfully screened in this set up.The program proposed for this Marie-Curie fellowship directly stems from the obvious complementarity of the two R and D programs. Collaboration, in particular through extended periods of work by Marc Peschanski and members of his team at CAPSANT, will allow the transfer of technology to the company, extending its offer to industrial partners to screening for therapies applicable to brain tumours.Conversely, CAPSANT scientists will provide high level training to Marc Peschanski and his team to all techniques they master that allow functional analysis of brain slices, including in particular electrophysiology and proteomics.
Original text from CORDIS.
Participants
- CAPSANT NEUROTECHNOLOGIES · SOUTHAMPTONCoordinatorCity levelUnited Kingdom
- INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE · PARISFrance
Links
Data: CORDIS, © European Union